ANTI-VEGFR2 HUMAN ANTIBODY FOR ANTI-ANGIOGENIC AND TARGETED CANCER THERAPY

    公开(公告)号:CA2981883A1

    公开(公告)日:2016-10-20

    申请号:CA2981883

    申请日:2016-04-12

    Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

    Anti-c-Met antibody and methods of use thereof

    公开(公告)号:AU2011296085A1

    公开(公告)日:2013-03-28

    申请号:AU2011296085

    申请日:2011-08-30

    Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.

    LUNG CANCER-TARGETED PEPTIDES AND APPLICATIONS THEREOF

    公开(公告)号:CA2678013A1

    公开(公告)日:2008-08-21

    申请号:CA2678013

    申请日:2008-02-12

    Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung canc er and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens f rom lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeti ng phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorub icin, the efficacy of these drugs against human lung cancer xenografts was i mproved, the survival rate increased, and the drug toxicity was reduced.

Patent Agency Ranking